BioNTech
BNTX
287 hedge funds and large institutions have $3.78B invested in BioNTech in 2024 Q1 according to their latest regulatory filings, with 50 funds opening new positions, 96 increasing their positions, 88 reducing their positions, and 43 closing their positions.
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
16% more first-time investments, than exits
New positions opened: 50 | Existing positions closed: 43
2% more funds holding
Funds holding: 282 → 287 (+5)
9% more repeat investments, than reductions
Existing positions increased: 96 | Existing positions reduced: 88
1% more call options, than puts
Call options by funds: $167M | Put options by funds: $165M
0.1% less ownership
Funds ownership: 17.33% → 17.23% (-0.1%)
13% less capital invested
Capital invested by funds: $4.34B → $3.78B (-$560M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$66.9M |
| 2 |
DM
Deerfield Management
New York
|
+$54.6M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$43M |
| 4 |
BlackRock
New York
|
+$25.6M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$18.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Temasek Holdings
Singapore
|
-$104M |
| 2 |
UBS AM
Chicago,
Illinois
|
-$74.9M |
| 3 |
First Trust Advisors
Wheaton,
Illinois
|
-$44M |
| 4 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$31.7M |
| 5 |
Morgan Stanley
New York
|
-$16.5M |
BNTX Hedge Fund Activity: Q1 2024 in Review
287 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in BioNTech (BNTX) for Q1 2024, worth a combined $3.78B — down 13% from $4.34B a quarter earlier.
Buyers outnumbered sellers: 50 funds opened new BNTX positions and 43 closed out — a net gain of 7 holders — while 96 added to existing stakes and 88 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $66.9M. The largest seller was Temasek Holdings, cutting an estimated $104M.
- 287 institutional investors held BioNTech (BNTX) as of Q1 2024, up from 282 in Q4 2023.
- Funds reported $3.78B of BioNTech stock for Q1 2024, down 13% quarter-over-quarter.
- 50 funds opened new BioNTech positions in Q1 2024 and 43 closed out, a net change of +7 holders.
- The largest BioNTech buyer in Q1 2024 was Fidelity Investments, an estimated $66.9M added.
- The largest BioNTech seller in Q1 2024 was Temasek Holdings, an estimated $104M sold.
Based on aggregated 13F filings for Q1 2024.